Pediatric influenza

Anna M Bramley1, Joseph Bresee, Lyn Finelli

  • 1Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Atlanta, GA, USA.

Pediatric Nursing
|February 20, 2010
PubMed

Insights

Annual influenza epidemics cause significant illness in children, particularly younger ones. Vaccination and antiviral treatments are key strategies to prevent and manage flu complications in children aged 6 months to 18 years.

Area of Science:

  • Pediatric Infectious Diseases
  • Epidemiology
  • Vaccinology

Background:

  • Influenza viruses cause significant annual epidemics in the US.
  • Pediatric morbidity from influenza includes increased outpatient visits, emergency department visits, hospitalizations, and deaths.
  • Younger children and those with underlying conditions face higher risks of complications.

Purpose of the Study:

  • To review the virological, clinical, and epidemiological features of seasonal influenza.
  • To discuss the role of seasonal influenza vaccination in children.
  • To outline the use of antiviral therapy for influenza prevention and treatment.

Main Methods:

  • Review of virological data on influenza strains.
  • Analysis of clinical presentations and outcomes in pediatric populations.
  • Epidemiological assessment of influenza trends and impact.
  • Evaluation of influenza vaccination efficacy and recommendations.
  • Review of antiviral treatment guidelines and effectiveness.

Main Results:

  • Influenza causes substantial annual pediatric morbidity and mortality.
  • Vaccination is recommended for all children aged 6 months to 18 years.
  • Antiviral treatment can reduce illness duration and complications.

Conclusions:

  • Seasonal influenza remains a significant public health concern for children.
  • Influenza vaccination is the most effective preventive measure.
  • Antiviral therapy provides an important adjunctive treatment option.

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...